4/A: Palisade Bio Amends Director RSU Grant

Palisade Bio, Inc. filed an amended Form 4 to correct a previously reported Restricted Stock Unit grant for Director Emil Chuang, reducing it from 510,700 to 60,600 RSUs.

Summary

• An amended Form 4 was filed to correct a previously reported Restricted Stock Unit (RSU) grant for Director Emil Chuang.
• The original grant of 510,700 RSUs was corrected, with 450,100 RSUs being rescinded.
• The corrected grant amount for Emil Chuang is 60,600 RSUs.
• Each RSU represents a contingent right to receive one share of common stock, or cash if the 2021 Equity Incentive Plan lacks sufficient reserved shares.
• The RSUs vest in three equal annual installments, with the first installment vesting on the earlier of the 2026 annual meeting of stockholders or October 6, 2026, subject to continuous service.

Sentiment

Score: 5

Explanation: Neutral. The filing is a correction of a previous error, which is neither inherently positive nor negative for the company's operational or financial performance, but rather a matter of accurate disclosure.

Positives

• Correction of an over-reported RSU grant ensures accurate disclosure of director compensation.

Negatives

• Initial misstatement of 450,100 RSUs in a previous filing required an amendment.

Risks

• Restricted Stock Units may be settled in cash if the Issuer's 2021 Equity Incentive Plan does not have sufficient shares reserved to issue upon settlement.

Future Outlook

The granted Restricted Stock Units are subject to a service-based vesting requirement and will vest in three equal annual installments, with the first installment occurring on the earlier of the 2026 annual meeting of stockholders or October 6, 2026.

Industry Context

This filing is a company-specific disclosure regarding director compensation and does not directly relate to broader industry trends or competitive landscape analysis.

Corporate Governance

Related Party Transactions

• Correction of a previously reported Restricted Stock Unit grant to Director Emil Chuang.

Stakeholder Impact

• Shareholders: Provides accurate information regarding director equity compensation, potentially reducing perceived dilution from the initially overstated grant.
• Management/Directors: Clarifies the actual equity award for Director Emil Chuang.

Next Steps

• Continued service of Director Emil Chuang for RSU vesting.
• Future vesting of RSUs in three equal annual installments.

Key Dates

Keywords

Palisade Bio, PALI, SEC Form 4/A, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Emil Chuang, Stock Grant Amendment